Incyte Earnings Beat Estimates; Jakafi Slowly Gaining Traction
By Catherine Shaffer
Friday, August 3, 2012
Incyte Corp.'s launch of Jakafi (ruxolitinib) for myelofibrosis continues to gather momentum as physicians gradually expand its use to less severely ill patients. The Wilmington, Del.-based company reported Jakafi sales of $31.9 million for the second quarter of 2012, and $53.1 million for the first six months of the year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.